ANN ARBOR, Mich., June 24 /PRNewswire/ -- NanoBio Corp. announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating NanoBio as one of the top biotechnology companies of 2008.
The editors of FierceBiotech evaluated hundreds of privately held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships and competitive market position. NanoBio was determined to be one of the "fiercest," proven by its creativity and innovations in the industry, according to the editors of FierceBiotech.
NanoBio, a spin-out from the University of Michigan, has developed a rich pipeline of anti-infective lotions and vaccines to combat a diverse range of bacteria, viruses and fungi, from MRSA to hepatitis B. Their platform uses a high-energy nanoemulsion to directly target and physically disrupt the outer membranes of pathogens, without toxicity or systemic absorption.
John Carroll, editor of FierceBiotech, said, "This University of Michigan spin-out has advanced its technology on topical agents into phase II trials and promises to make big gains in the way that vaccines are developed and manufactured. The data look promising, a phase III looms, partnerships beckon, and then there's the lure of a possible IPO in the not-too-distant future. For a nano-bio company, NanoBio is well ahead of the pack."
NanoBio's lead treatments are topical lotions for cold sores and nail fungus. Recent data from phase 2 trials demonstrate that their topical treatment for cold sores achieves the efficacy of leading systemic treatments with none of their safety, toxicity or drug interaction concerns. In addition, animal studies indicate that NanoBio's vaccines quickly trigger robust immunity -- without adverse effects -- against a wide array of viruses and bacteria, including influenza, hepatitis B, RSV and anthrax.
"It is really gratifying to have our work recognized by a major voice
|SOURCE NanoBio Corporation|
Copyright©2008 PR Newswire.
All rights reserved